此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Ablative Fractional Laser for Sclerotic GVHD-Associated Joint Contractures

Ablative Fractional Laser Resurfacing for the Treatment of Scars and Contractures Caused by Sclerotic Skin Changes Chronic Graft Versus Host Disease

Graft versus host disease (GVHD) is a common complication of allogeneic stem cell transplant.Chronic GVHD is characterized by skin thickening and tightening. Advanced sclerosis can lead to reduced range of motion and incapacitating joint contractures. Once present, there are few therapeutic options. We will treat sclerosis and limb contractures with an ablative fractional laser, a device FDA-approved for scar treatment. This approach has successfully treated contracturesdue to burn scars.

研究概览

研究类型

介入性

注册 (实际的)

8

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • Abramson Cancer Center of the University of Pennsylvania

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Subjects must be able to give informed consent
  • All adult patients (18 years of age or older) Severe sclerotic skin changes of chronic graft versus host disease meeting a score of 3 on the NIH consensus criteria for organ scoring of chronic GVHD,
  • a score defined by deep sclerotic features with hidebound skin which cannot be pinched together, resulting in impaired motion.
  • According to the NIH criteria, the patient need not have widespread cutaneous GVHD; hidebound skin OR impaired mobility receive a score of 3 (highest score).
  • Demonstrable range of motion limitations and joint contractures due to sclerotic GVHD across a specific joint / limb amenable to laser therapy must be present. - - Patients must note an inability to bend the joint (e.g. foot, wrist, elbow) freely which compromises the ability to perform specific tasks (e.g. walking up or down stairs, grabbing / making a fist, lifting or raising thearms over the head). As these functional limitations are by their nature subjective (and NIH scoring criteria are themselves subjective) determination of eligibility will be made by the investigator.
  • ECOG Performance Status shall be 0-3

Exclusion Criteria:

  • Persons unable to provide informed consent Pregnant or nursing women, or children under age 18
  • Active infections such as herpes simplex virus (HSV) Acute, untreated medical problems such as poorly-controlled diabetes, decompensated heart failure, etc.
  • There are no specific contraindications to use of the laser based on skin pigmentation, sun sensitivity, history of keloids, use of specific medications, etc.
  • Appropriateness for trial entry will be determined on an individual basis by the study investigators.
  • Patients with ECOG Performance Status 3 will be excluded.
  • Patients with ANC 1500,PLT 50, or Hgb 8.0 will be excluded.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:不适用
  • 介入模型:单组作业

武器和干预

参与者组/臂
干预/治疗
实验性的:rAblative Fractional Laser for Sclerotic GVHD-Associated Joint
Range of motion limitations and joint contractures due to sclerotic GVHD across a specific joint / limb"
Perform ablative fractional resurfacing using a 10,600nm carbon dioxide (CO2) laser targeted to thickened, sclerotic plaques causing range of motion limitation and contracture across joints.
Patients will undergo ultrasound of the planned treatment site to measure skin thickness and blood flow via Doppler ultrasound.
standard 4mm punch biopsy of the skin at the planned treatment site for histologic assessment of skin thickness and sclerosis.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Subjects Who Show Improvement in Range of Motion, Flexion, and Extension
大体时间:5 months from time point zero / baseline
Range of motion (flexion, extension, supination, pronation) of the target joint (measured in degrees, using a goniometer).
5 months from time point zero / baseline
Number of Subjects With Evidence of Collagen Remodeling (Increased Dermal Echogenicity) Compared to Baseline
大体时间:3 months after final laser session (5 months after time zero / baseline)
Measurement of skin echogencity (brightness) in comparison with pre-therapy images of the same areas using high-resolution ultrasound.
3 months after final laser session (5 months after time zero / baseline)
Number of Subjects Who Show Decrease in Skin Thickness and Sclerosis With Collagen Remodeling as Measured by Before and After Skin Biopsies Biopsy
大体时间:baseline and 3 months after final laser session
Trichcrome stain, collagen fiber number and thickness, Herovici stain, elastic fiber length, and dermal thickness.
baseline and 3 months after final laser session

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Robert Micheletti, MD、Abramson Cancer Center of the University of Pennsylvania

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2013年11月11日

初级完成 (实际的)

2016年8月1日

研究完成 (实际的)

2016年8月19日

研究注册日期

首次提交

2016年8月24日

首先提交符合 QC 标准的

2016年8月24日

首次发布 (估计)

2016年8月26日

研究记录更新

最后更新发布 (实际的)

2020年4月16日

上次提交的符合 QC 标准的更新

2020年4月6日

最后验证

2020年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • UPCC 14613

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅